



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

**Applicant:** Robert J. Peach et al.  
**Serial No.:** 09/865,321  
**Filed:** May 23, 2001  
**Docket:** D0028PNP;30436.57USU1  
**Title:** SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 22, 2002.

By: 

Name: Tracy Truick

55 South Lake Avenue, Suite 710  
Pasadena, California 91101  
November 22, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Preliminary Amendment (10 pages)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 South Lake Avenue, Suite 710  
Pasadena, California 91101  
(626) 395-7801

By: 

Name: Sarah B. Adriano  
Reg. No.: 34,470  
Initials: SBA  
Customer No. 26,941



#16/c

Dkt. D0028PNP; 30436.57USU1 SBA/RDG

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Robert J. Peach, et al.

Serial No.: 09/865,321

Patent Examiner: Not yet known

Filed: May 23, 2001

Group Art Unit: 1646

Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

55 South Lake Ave., Suite 710  
Pasadena, California 91101  
November 22, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

DEC 06 2002

Dear Sir:

TECH CENTER 1600/2900

**PRELIMINARY AMENDMENT**

Please amend the subject application as follows.

**In the Claims:**

Please cancel claims 1-66 without prejudice to pursue the subject matter of these claims in another patent application. Please add new claims 67-96 as follows:

- C1
67. (NEW ) A soluble CTLA4 mutant molecule which binds CD80 and/or CD86 comprising an extracellular domain of CTLA4 as shown in SEQ ID NO. 8 beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at position 150, or a portion thereof, wherein in the extracellular